Pharmacovigilance in the EU: What Companies Need to Know

For pharmaceutical and biotech companies entering or operating in the European market, pharmacovigilance (PV) is a critical regulatory requirement. A well-structured pharmacovigilance system ensures that the safety of medicinal products is continuously monitored once they are on the market.

However, many companies—especially startups or companies new to Europe—are unsure how extensive their PV obligations are and how to implement them efficiently.

This article provides an overview of EU pharmacovigilance requirements, key system components, and common challenges companies face when setting up a compliant PV system.

What is Pharmacovigilance?

Pharmacovigilance refers to the science and activities related to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problems.

In the European Union, pharmacovigilance requirements are defined in:

• EU Directive 2001/83/EC

• Regulation (EC) No 726/2004

• Good Pharmacovigilance Practice (GVP) guidelines issued by the European Medicines Agency (EMA)

The objective is to ensure that the benefit–risk balance of medicines remains positive throughout the product lifecycle.

Pharmacovigilance activities begin during clinical development but become particularly important after marketing authorisation, when medicines are used by larger and more diverse patient populations.

Key Components of an EU Pharmacovigilance System

Companies holding a Marketing Authorisation (MAH) in the EU must establish and maintain a pharmacovigilance system. The core elements typically include:

EU Qualified Person for Pharmacovigilance (QPPV)

Every marketing authorisation holder must appoint an EU QPPV responsible for the establishment and maintenance of the PV system.

The QPPV must:

• Reside and operate in the EU

• Be continuously available for PV matters

• Ensure compliance with EU pharmacovigilance legislation

Pharmacovigilance System Master File (PSMF)

The PSMF describes the pharmacovigilance system used by the company.

It typically includes:

• Organisational structure

• Roles and responsibilities

• PV processes and procedures

• Computerised systems

• Safety database information

• Oversight of partners and vendors

The PSMF must be maintained and available for inspection at any time.

Adverse Event Collection and Reporting

Companies must collect and report Individual Case Safety Reports (ICSRs).

Typical reporting timelines include:

• Serious adverse reactions: within 15 days

• Non-serious adverse reactions: within 90 days

Reports are submitted to EudraVigilance, the European safety database managed by the EMA.

Signal Detection and Risk Management

Beyond individual case reporting, pharmacovigilance also involves:

• Signal detection

• Benefit–risk evaluation

• Periodic Safety Update Reports (PSURs)

• Risk Management Plans (RMPs)

These activities ensure that new safety information is continuously evaluated.

Pharmacovigilance Inspections

Regulatory authorities may conduct pharmacovigilance inspections to verify compliance with EU requirements.

During inspections, regulators typically review:

• The PSMF

• SOPs and quality system documentation

• Case processing workflows

• Vendor oversight

• Training records

• Signal management processes

Companies without a structured PV quality system often struggle during inspections, particularly when documentation is incomplete or responsibilities are unclear.

Common Challenges for Biotech Companies

Many biotech companies face similar challenges when establishing pharmacovigilance systems:

Limited internal PV expertise

Startups often lack dedicated PV staff.

Overly complex quality systems

Large pharma-style systems may be unnecessarily heavy for smaller organisations.

Unclear responsibilities between partners

Safety activities may be split between CROs, distributors, and internal teams.

Documentation gaps

Incomplete SOPs or PSMF structures are common findings during inspections.

A proportionate and scalable PV system is therefore essential, especially for companies preparing for their first EU marketing authorisation.

Building a Practical Pharmacovigilance System

An effective pharmacovigilance system should be:

• Compliant with EU GVP requirements

• Clearly documented

• Proportionate to the size and complexity of the organisation

• Easy to maintain over time

Key building blocks typically include:

• PV SOPs and procedures

• PSMF development and maintenance

• Vendor oversight structures

• Training systems

• Audit readiness

When implemented correctly, pharmacovigilance becomes not only a regulatory obligation but also a structured way to ensure patient safety and product quality.

Pharmacovigilance Support for Life Science Companies

At OZQA, we support pharmaceutical and biotech companies with EU pharmacovigilance compliance, including:

• PV system setup

• Development of SOPs and PSMF documentation

• GVP compliance support

• Inspection readiness

• Ongoing pharmacovigilance consulting

Our focus is on clear, practical systems that meet regulatory expectations without unnecessary complexity.